Clinical Trial Update: An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) [Phase 3]

View source ↗

Summary

Open-label extension study in Phase 3 to evaluate long-term safety and tolerability of Pelacarsen (TQJ230) after completion of a prior trial, sponsored by Novar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiovascular Disease and Lipoprotein(a) | Phase 3 | Status: RECRUITING